Harlan S. Robins
Known title: Chief Scientific OfficerCIK: 0001780851
Associated companies
Transaction History
| ADPT | ▲ Buy | Option Exercise | 284,800 | $1.9M | 7/21/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 278,698 | $6.1M | 7/21/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 213,702 | $4.7M | 7/21/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 146,889 | $3.3M | 7/2/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 239,351 | $5.2M | 7/2/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 6,160 | $111K | 6/16/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 100,000 | $1.7M | 6/15/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 10,000 | $149K | 4/8/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 140,666 | $1.9M | 3/11/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 329,600 | $4.3M | 3/11/2026 | View on chart |
| ADPT | ▲ Buy | Grant | 709,220 | $0 | 3/6/2026 | View on chart |
| ADPT | ▲ Buy | Grant | 127,813 | $0 | 3/4/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 14,233 | $235K | 3/3/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 10,000 | $157K | 3/2/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 8,120 | $154K | 2/3/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 34,668 | $645K | 2/2/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 10,000 | $164K | 1/6/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 10,000 | $166K | 12/4/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 27,212 | $506K | 12/3/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 10,000 | $148K | 11/10/2025 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 68,412 | $432K | 5/1/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 68,412 | $503K | 5/1/2025 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 1,698 | $11K | 3/24/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 1,698 | $15K | 3/24/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 40,603 | $283K | 3/5/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 56,053 | $392K | 3/5/2025 | View on chart |
| ADPT | ▲ Buy | Grant | 355,000 | $0 | 3/4/2025 | View on chart |
| ADPT | ▲ Buy | Grant | 354,610 | $0 | 3/4/2024 | View on chart |
| ADPT | ▲ Buy | Grant | 354,610 | $0 | 3/6/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 4,517 | $54K | 3/7/2022 | View on chart |
| ADPT | ▲ Buy | Grant | 247,117 | $0 | 3/4/2022 | View on chart |
| ADPT | ▼ Sell | Open Market | 300 | $9K | 11/18/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 300 | $2K | 11/18/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 3,700 | $24K | 11/17/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 3,700 | $119K | 11/17/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 3,700 | $24K | 10/21/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 3,700 | $125K | 10/21/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 3,700 | $24K | 10/20/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 3,700 | $125K | 10/20/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 3,800 | $25K | 10/19/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 300 | $10K | 10/19/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 3,500 | $118K | 10/19/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 3,895 | $25K | 10/8/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 3,895 | $128K | 10/8/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 200 | $7K | 10/7/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 3,895 | $25K | 10/7/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 3,695 | $124K | 10/7/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 3,895 | $25K | 10/6/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 3,895 | $126K | 10/6/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 3,895 | $25K | 9/15/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 2,995 | $109K | 9/15/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 900 | $34K | 9/15/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 3,895 | $25K | 9/14/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 2,795 | $102K | 9/14/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 1,100 | $41K | 9/14/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 3,895 | $25K | 9/13/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 2,995 | $112K | 9/13/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 900 | $34K | 9/13/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 3,895 | $25K | 8/27/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 961 | $33K | 8/27/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 2,934 | $103K | 8/27/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 3,895 | $25K | 8/26/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 3,895 | $132K | 8/26/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 3,895 | $25K | 8/25/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 3,895 | $133K | 8/25/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism
Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism. Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.